Global Lung Cancer Screening: A Clear Roadmap for India
Effective lung cancer screening using low-dose computed tomography (LDCT) is shifting from clinical trial validation to real-world execution. However, healthcare systems in low- and middle-income countries face distinct logistical hurdles. In India, clinicians frequently diagnose lung cancer at advanced, metastatic stages. Therefore, establishing pragmatic detection models is an urgent clinical imperative.
Rethinking Lung Cancer Screening for Indian Realities
Western screening guidelines rely heavily on cumulative smoking pack-years. However, Dr Abhishek Shankar from AIIMS New Delhi highlights that Indian epidemiology differs substantially. In India, nearly half of lung cancer patients are non-smokers. Consequently, directly adopting North American or European eligibility criteria would leave many at-risk individuals undetected.
Furthermore, ambient air pollution, indoor biomass fuel combustion, and second-hand smoke contribute heavily to oncogenesis. Occupational carcinogen exposure also amplifies vulnerability across industrial belts. Therefore, Indian screening frameworks must integrate multivariable risk assessment rather than isolated smoking thresholds.
Four Core Pillars of Implementation
The Lung Cancer Policy Network recently synthesized critical implementation evidence from international programs. Specifically, their latest report establishes four foundational priorities for scalable cancer screening:
- Precision risk identification: Programs must target high-risk cohorts through validated multivariable models rather than age and smoking history alone.
- Targeted community outreach: Providers should deploy systematic invitations to overcome stigma and reach historically marginalized populations.
- Holistic public health integration: Screening centers should integrate smoking cessation support, respiratory health education, and cardiovascular assessments.
- Health system embedding: Facilities must secure reliable diagnostic pathways, nodule management protocols, and prompt treatment capacity.
Addressing Non-Smoking Risks and Air Pollution
To generate localized evidence, AIIMS New Delhi has spearheaded proactive initiatives such as the Indian Lung Screening Trial and the AIRCARE study. Notably, the AIRCARE project investigates the biological and oncological impact of chronic fine particulate matter (PM2.5) exposure.
Additionally, researchers are evaluating specific genetic and molecular signatures linked to air pollution in Delhi-NCR. As a result, these ongoing studies will help clinicians build risk-stratification models tailored to India's unique environmental exposures. Thus, local evidence generation remains essential for defining cost-effective screening eligibility.
Integrating Care Pathways in Health Systems
A screening initiative cannot function as a standalone imaging protocol. Indeed, an abnormal LDCT scan requires structured nodule management pathways to avoid unnecessary invasive biopsies. Therefore, tertiary centers must link screening directly with primary health networks and thoracic & respiratory diagnostic frameworks.
Moreover, health systems must guarantee timely downstream thoracic surgery, radiation oncology, and targeted therapies. Without adequate therapeutic infrastructure, earlier detection cannot reduce cancer mortality. By tailoring global implementation lessons, India can establish sustainable, equitable screening pathways for high-risk populations.
Frequently Asked Questions
Q1: Why can India not directly adopt Western screening guidelines?
Western guidelines focus almost exclusively on heavy tobacco smoking history. In contrast, up to 50% of Indian lung cancer patients are non-smokers who develop disease due to air pollution, biomass smoke, and occupational carcinogens.
Q2: What is the primary role of LDCT in lung cancer detection?
Low-dose computed tomography detects pulmonary nodules at early, resectable stages. Consequently, LDCT significantly lowers lung cancer mortality compared to standard chest radiography when applied to appropriately risk-stratified cohorts.
Q3: How does the AIRCARE study at AIIMS Delhi contribute to screening policy?
The AIRCARE study examines the molecular and clinical impact of chronic PM2.5 exposure. Therefore, its findings will support risk-prediction models tailored specifically to environmental hazards in India.
References
- Global lung cancer screening lessons offer roadmap for India: AIIMS expert - ETHealthworld
- Lung Cancer Policy Network. Advancing Lung Cancer Screening: Learning from Implementation in Europe. 2026.
- Shankar A, Saini D, Dubey A, et al. Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward. Translational Lung Cancer Research.
